Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

about

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

Item

http://www.wikidata.org/entity/Q50042437

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

@en

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

@nl

type

Item

label

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

@en

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

@nl

prefLabel

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

@en

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

@nl

P1476

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

@en

P2093

Daniel Verduzco

http://www.w3.org/2001/XMLSchema#string

Fumi Kinose

http://www.w3.org/2001/XMLSchema#string

Uwe Rix

http://www.w3.org/2001/XMLSchema#string

Vernon K Sondak

http://www.w3.org/2001/XMLSchema#string

Zeynep Eroglu

http://www.w3.org/2001/XMLSchema#string

P2860

The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling

Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

A landscape of driver mutations in melanoma

A comprehensive catalogue of somatic mutations from a human cancer genome

Genome sequencing identifies a basis for everolimus sensitivity

Beyond BRAF: where next for melanoma therapy?

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

Elucidating distinct roles for NF1 in melanomagenesis

P304

73-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-17-0196

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Brent M Kuenzi

Keiran S M Smalley

P577

2017-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29133622

http://www.w3.org/2001/XMLSchema#string

P921

ceritinib

P932

5752595

http://www.w3.org/2001/XMLSchema#string